Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 23,957 shares at $24.53 ($597K) on 2024-07-25, disclosed to the SEC on 2024-07-29.
Scheduled sale ($597k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.53 | 3,793 | $93K | 15.6% |
| 2 | $24.53 | 3,793 | $93K | 15.6% |
| 3 | $25.10 | 8,164 | $205K | 34.3% |
| 4 | $25.10 | 8,164 | $205K | 34.3% |
| 5 | $25.83 | 43 | $1K | 0.2% |
| Total | $24.92 avg | 23,957 |
| $597K |
| 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |